









Markets
/
Stocks
/
nasdaq-dare
/

Dare Bioscience Inc

DARE

2.120USD

+0.040+1.92%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

19.14MMarket Cap

LossP/E TTM



Dare Bioscience Inc

2.120

+0.040+1.92%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

105 / 175

Overall Ranking

349 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.750

Target Price

+416.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.78K.

Overvalued

The company’s latest PE is -0.21, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 999.55K shares, decreasing 35.59% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 328.33K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.66.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.74, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.74

Change



Financials

5.53

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.35

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.20, which is 27.91% below the recent high of -0.26 and -8161.68% above the recent low of -16.90.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 105/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Dare Bioscience Inc is 11.50, with a high of 12.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.750

Target Price

+416.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Dare Bioscience Inc

DARE

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.92, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 2.21 and the support level at 1.98, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.92

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.028

Neutral

RSI(14)

49.037

Neutral

STOCH(KDJ)(9,3,3)

50.367

Buy

ATR(14)

0.076

High Vlolatility

CCI(14)

14.993

Neutral

Williams %R

42.230

Buy

TRIX(12,20)

-0.174

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.075

Buy

MA10

2.102

Buy

MA20

2.085

Buy

MA50

2.257

Sell

MA100

2.547

Sell

MA200

2.821

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 11.29%, representing a quarter-over-quarter increase of 2.13%. The largest institutional shareholder is The Vanguard, holding a total of 328.33K shares, representing 2.44% of shares outstanding, with 26.58% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

328.33K

+13.76%

AMH Equity, Ltd.

164.30K

+9.53%

Susquehanna International Group, LLP

58.16K

+43.32%

Geode Capital Management, L.L.C.

95.91K

+3.51%

Johnson (Sabrina Martucci)

80.17K

+0.00%

Renaissance Technologies LLC

Star Investors

70.59K

+2.77%

Walters-Hoffert (Lisa)

36.96K

State Street Global Advisors (US)

23.52K

Steele Robin Joan

20.52K

+0.00%

BlackRock Institutional Trust Company, N.A.

16.97K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.19, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.